Search Within

Matthew David Hellmann

Formats
  1. Meeting Abstract (210)
  2. Journal Article (187)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (412)
  2. Solid Tumor Oncology Division (412)
  3. Thoracic Oncology (412)
  4. GSK Faculty (140)
  5. Department of Pathology and Laboratory Medicine (112)
  6. Weinberg Fellows (103)

More Groups

People
  1. Hira Rizvi (97)
  2. Mark Kris (71)
  3. Jamie Chaft (68)
  4. Charles Rudin (67)
  5. Jedd Wolchok (53)
  6. Gregory Riely (49)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (34)
  5. 2021 (40)
  6. 2020 (55)

More Years

Publications
  1. Journal of Clinical Oncology (91)
  2. Journal of Thoracic Oncology (58)
  3. Annals of Oncology (49)
  4. Journal for ImmunoTherapy of Cancer (30)
  5. Cancer Research (24)
  6. Clinical Cancer Research (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (96)
  2. Elsevier Inc. (75)
  3. American Association for Cancer Research (57)
  4. Oxford University Press (53)
  5. Biomed Central Ltd (30)
  6. Nature Publishing Group (21)

More Publishers

Results (412)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune-related adverse events associated with immune checkpoint blockade
    Journal Article

    Postow, M. A.; Sidlow, R.; Hellmann, M. D.
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer
    Journal Article

    Arbour, K. C.; Jordan, E.; Kim, H. R.; Dienstag, J.; Yu, H. A.; Sanchez-Vega, F.; Lito, P.; Berger, M.; Solit, D. B.; Hellmann, M.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Dynamics of immune-mediated thyroid dysfunction in patients with advanced renal cell carcinoma receiving checkpoint inhibitor therapy
    Meeting Abstract

    Osorio, J. C.; Patil, S.; Coskey, D. T.; Carlo, M. I.; Feldman, D. R.; Hellmann, M. D.; Voss, M. H.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma
    Meeting Abstract

    Miao, D.; Margolis, C.; Martini, D.; Mullane, S. A.; Cullen, D.; Horak, C.; Wind-Rotolo, M.; Hellmann, M. D.; Voss, M. H.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Use of PD-1 pathway inhibitors among patients with non-small cell lung cancer (NSCLC) and preexisting autoimmune disorders
    Meeting Abstract

    Leonardi, G. C.; Gainor, J. F.; Azimi, R. S.; Riess, J.; Rizvi, H.; Hellmann, M. D.; Awad, M. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010
    Meeting Abstract

    Hellmann, M. D.; Ma, J.; Garon, E. B.; Hui, R.; Gandhi, L.; Soria, J. C.; Anderson, K. M.; Lubiniecki, G. M.; Piperdi, B.; Herbst, R. S.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients
    Meeting Abstract

    Fong, L.; Forde, P. M.; Powderly, J. D.; Goldman, J. W.; Nemunaitis, J. J.; Luke, J. J.; Hellmann, M. D.; Kummar, S.; Doebele, R. C.; Mahadevan, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors
    Meeting Abstract

    Burris, H. A.; Gordon, M. S.; Hellmann, M. D.; LoRusso, P.; Emens, L. A.; Hodi, F. S.; Lieu, C. H.; Infante, J. R.; Tsai, F. Y. C.; Eder, J. P.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gandhi, L.; Johnson, M. L.; Opyrchal, M.; Ramalingam, S.; Janne, P.; Chachoua, A.; Ordentlich, P.; Brouwer, S.; Sankoh, S.; Schmidt, E.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save